| Netarsudil Mesylate | Aerie pharma | ||
| 0.02% ; Ophthalmic solution |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. | |||
|
Yes
| |||
| Rhopressa | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | *** ********* | *** ********* | *** ********* | ******* | ******* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | *** ********* | ******* | ****** ************ / ******** ********* ******* |
| ********* | ******* ***** ******** ************ | **** *** | **** *** | ******* ***** ******** ************ | ******* ***** ******** ************ | ******* ***** ******** ************ | **** *** | ******* ***** ******** ************ | ******* ***** ******** ************ | **** *** | **** *** | ******* ***** ******** ************ | ******* ***** ******** ************ | *** ********* (***** ******) |
| **** ********* ********** *** *** ********* ** ******* | ****- *** *****-*****-************ ***** ********* *** *********** ********* ********* | *********** ******* | **** ********* ********** *** *** ********* ** ******* | ****- *** *****-*****-************ ***** ********* *** *********** ********* ********* | ****- *** *****-*****-************ ***** ********* *** *********** ********* ********* | **** ********* ********** *** *** ********* ** ******* | ************ *** ******** ******** ** ******** *********** ******** | **** ********* ********** *** *** ********* ** ******* | **** ********* ********** *** *** ********* ** ******* | ****- *** *****-*****-************ ***** ********* *** *********** ********* ********* | ****- *** *****-*****-************ ***** ********* *** *********** ********* ********* | *********** ******* | *********** ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | *** / ********* | **** **, **** | ******* / ********* **** | ******** | ******* *** **** *** *** **** |
| ********* | *** / *** | **** **, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|